BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, Alona Zer et al.|Journal of Thoracic Oncology|2018Cited by 220
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataElizabeth Dudnik, Nir Peled, Mor Moskovitz et al.|Lung Cancer|2017Cited by 104
ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous ThromboembolismAlona Zer, Frances A. Shepherd, Mor Moskovitz et al.|Clinical Lung Cancer|2016Cited by 100
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Nir Peled, Elias Bshara et al.|Lung Cancer|2018Cited by 75
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg et al.|OncoImmunology|2021Cited by 70